Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation

被引:73
作者
Horan, JT
Francis, CW
机构
[1] Univ Rochester, Sch Med & Dent, Dept Pediat, Hematol Unit, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Med, Vasc Med Unit, Rochester, NY 14642 USA
关键词
fibrin(ogen) degradation products; D-dimer; soluble fibrin; disseminated intravascular coagulation; DIC; endotoxin;
D O I
10.1055/s-2001-18870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disseminated intravascular coagulation (DIC) is characterized by activation of hemostasis and fibrinolysis resulting in the formation of thrombin and plasmin, and the characteristic effects of these enzymes on plasma fibrinogen can be useful in diagnosis. Thrombin cleaves fibrinopeptides from fibrinogen, forming fibrin monomer that rapidly polymerizes to form a clot. Small amounts can circulate in plasma as "soluble fibrin," which may have a complex composition and include fibrinogen and a variable amount of cross-linking. Plasmic degradation of cross-linked fibrin forms a heterogeneous group of degradation products reactive in assays for D-dimer, and their levels provide a measure of the amount of fibrin formation and lysis. Caution should be exercised in comparing quantitative results using different assays because of problems with standardization and variable reactivity with different molecular forms. Marked elevations of fibrin(ogen) degradation products are a constant finding in experimental animal models of DIC. In human models of DIC resulting from endotoxin infusion, D-dimer is elevated early and high levels persist, reflecting lysis of microvascular fibrin deposits. Elevated levels of D-dimer and soluble fibrin are very sensitive for the diagnosis of DIC, and a normal level has a high negative predictive value. Serial monitoring of soluble fibrin or D-dimer assays may be of value in evaluating the response to therapy and possibly in identifying at-risk patients.
引用
收藏
页码:657 / 666
页数:10
相关论文
共 61 条
[21]  
Gando S, 1996, THROMB HAEMOSTASIS, V75, P224
[22]  
GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35
[23]  
GODAL HC, 1966, SCAND J HAEMATOL, V3, P342
[24]   SUBUNIT AND MACROMOLECULAR STRUCTURE OF CIRCULATING FIBRIN FROM OBSTETRIC PATIENTS WITH INTRA-VASCULAR COAGULATION [J].
GRAEFF, H ;
HAFTER, R ;
BACHMANN, L .
THROMBOSIS RESEARCH, 1979, 16 (3-4) :313-328
[25]   CLEAVAGE OF BLOOD-COAGULATION FACTOR-XIII AND FIBRINOGEN BY THROMBIN DURING INVITRO CLOTTING [J].
GREENBERG, CS ;
MIRAGLIA, CC ;
RICKLES, FR ;
SHUMAN, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (05) :1463-1470
[26]   NORMAL AND FIBRINEMIC PATIENT PLASMA CONTAIN HIGH-MOLECULAR-WEIGHT CROSSLINKED FIBRIN(OGEN) DERIVATIVES WITH INTACT FIBRINOPEPTIDE-A [J].
GRON, B ;
BENNICK, A ;
NIEUWENHUIZEN, W ;
BROSSTAD, F .
THROMBOSIS RESEARCH, 1990, 57 (02) :259-270
[27]   COMPARISON OF METHODS FOR DETECTING SOLUBLE FIBRIN IN PLASMA - AN INVITRO STUDY [J].
HALVORSEN, S ;
SKJONSBERG, OH ;
RUYTER, R ;
GODAL, HC .
THROMBOSIS RESEARCH, 1990, 57 (04) :489-497
[28]  
HIGGINS DL, 1983, J BIOL CHEM, V258, P9276
[29]   FIBRIN POLYMERIZATION AND RELEASE OF FIBRINOPEPTIDE-B BY THROMBIN [J].
HURLETJENSEN, A ;
CUMMINS, HZ ;
NOSSEL, HL ;
LIU, CY .
THROMBOSIS RESEARCH, 1982, 27 (04) :419-427
[30]   INCORPORATION OF FIBRINOGEN INTO SOLUBLE FIBRIN COMPLEXES [J].
JAKOBSEN, E ;
LY, B ;
KIERULF, P .
THROMBOSIS RESEARCH, 1974, 4 (04) :499-507